Stocktoria

CytoDyn Inc. CYDY

OTC · stock · Pharmaceutical Preparations · website · IPO 2005-11-17 · LEI

CytoDyn Inc. statistics & valuation

Market cap$339.7M
Net debt$26.5M
Enterprise value USD$366.2M
Earnings yield EBIT/EV-10.5%

Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
80.10% 2017201820192020202120222023202420252026
Operating margin (%)
-54663.20% 2017201820192020202120222023202420252026
Return on equity (%)
2017201820192020202120222023202420252026
Shares outstanding
149.5M 216.7M 329.4M 519.0M 625.7M 719.6M 918.6M 1.06B 1.25B 1.37B 2017201820192020202120222023202420252026
Net debt ($)
-$1.2M $8.3M $38.0M $43.2M $41.9M $33.4M $26.5M 2017201820192020202120222023202420252026
Share buybacks ($)
2017201820192020202120222023202420252026
Return on assets (%)
-319.80% -1023.70% -290.90% -277.00% -133.60% -722.40% -706.90% -447.60% 20.80% -305.60% 2017201820192020202120222023202420252026
Free cash flow margin (%)
2017201820192020202120222023202420252026
Debt / equity (×)
2017201820192020202120222023202420252026
EPS ($)
-$0.23 -$0.33 -$0.30 -$0.31 -$0.10 -$0.05 $0.00 -$0.03 2017201820192020202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin————80.1%—————
Operating margin————-54663.2%—————
Net margin————-79255.6%—————
Return on assets-305.6%20.8%-447.6%-706.9%-722.4%-133.6%-277.0%-290.9%-1023.7%-319.8%
Return on equity38.9%-3.9%42.7%72.9%223.3%839.6%5640.3%681.2%381.1%2335.3%
Debt / equity-0.35×-0.47×-0.39×-0.42×-0.45×-2.01×——-0.00×—
Current ratio0.260.250.130.090.090.240.830.200.201.00

Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.